<SEC-DOCUMENT>0001144204-14-054727.txt : 20140908
<SEC-HEADER>0001144204-14-054727.hdr.sgml : 20140908
<ACCEPTANCE-DATETIME>20140908131211
ACCESSION NUMBER:		0001144204-14-054727
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20140904
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140908
DATE AS OF CHANGE:		20140908

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cellectar Biosciences, Inc.
		CENTRAL INDEX KEY:			0001279704
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				043321804
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36598
		FILM NUMBER:		141090079

	BUSINESS ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716
		BUSINESS PHONE:		617-244-1616

	MAIL ADDRESS:	
		STREET 1:		3301 AGRICULTURE DRIVE
		CITY:			MADISON
		STATE:			WI
		ZIP:			53716

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVELOS THERAPEUTICS, INC.
		DATE OF NAME CHANGE:	20050617

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	COMMON HORIZONS INC
		DATE OF NAME CHANGE:	20040211
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>v388646_8k.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B><BR>
Washington, D.C. 20549</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; width: 25%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of Report: September 4, 2014<BR>
(<I>Date of earliest event reported</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CELLECTAR BIOSCIENCES, INC.</B><BR>
(<I>Exact name of registrant as specified in its charter</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 10pt; padding-left: 10pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><B>Delaware</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 10pt; padding-left: 10pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><B>333-119366</B></P></TD>
    <TD STYLE="width: 33%; padding-right: 10pt; padding-left: 10pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; border-bottom: Black 0.5pt solid; margin-bottom: 0pt; text-align: center"><B>04-3321804</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 10pt; padding-left: 10pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(State or other jurisdiction</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>of incorporation)</I></P></TD>
    <TD STYLE="padding-right: 10pt; padding-left: 10pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Commission</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>File Number)</I></P></TD>
    <TD STYLE="padding-right: 10pt; padding-left: 10pt; text-align: center">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(IRS Employer</I></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>Identification Number)</I></P></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>3301 Agriculture Drive </B><BR>
<B>Madison, WI 53716</B><BR>
(<I>Address of principal executive offices</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>(608) 441-8120</B><BR>
(<I>Registrant&rsquo;s telephone number, including area code</I>)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: -0.5in"><FONT STYLE="font-family: Wingdings">&#168;</FONT>
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 7.01</B></TD><TD><B>REGULATION FD DISCLOSURE</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">On September 4, 2014, we issued a press release announcing that
the U.S. Food &amp; Drug Administration (FDA) had accepted the Company&rsquo;s investigational new drug (IND) application to begin clinical
study of I-131-CLR1404, a highly-selective, cancer-targeting radiopharmaceutical, in patients with relapsed or refractory multiple
myeloma, an incurable cancer of plasma cells. A copy of the press release is furnished as Exhibit 99.1 and is incorporated by reference
herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">On September 5, 2014, we issued
a press release announcing that Dr. Simon Pedder, chief executive officer, would be presenting a company overview at the Rodman
&amp; Renshaw 16th Annual Global Investment Conference being held September 8 - 10, 2014 at the New York Palace Hotel in New York
and the Aegis Capital Healthcare and Technology Conference being held September 10 - 13, 2014 at the Encore at Wynn in Las Vegas.</FONT>
<FONT STYLE="font-size: 10pt">A copy of the press release is furnished as Exhibit 99.2 and is incorporated by reference herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 1in; text-align: left"><B>ITEM 9.01</B></TD><TD><B>FINANCIAL STATEMENTS AND EXHIBITS</B></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(d)</TD><TD>Exhibits</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 78%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated September 4, 2014, entitled &ldquo;Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated September 5, 2014, entitled &ldquo;Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-transform: uppercase; text-align: center">SIGNATURE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">Dated: September 8, 2014</TD>
    <TD COLSPAN="2"><B>CELLECTAR BIOSCIENCES, INC.</B></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
    <TD STYLE="width: 4%">By:&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 46%"><I>/s/ Chad J. Kolean</I></TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">Name:&nbsp;&nbsp;Chad J. Kolean<BR>Title:&nbsp;&nbsp;&nbsp;&nbsp;Vice President and Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>EXHIBIT INDEX</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: black 1pt solid; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">Number</FONT></TD>
    <TD STYLE="width: 2%; font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 78%; border-bottom: black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt">Title</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated September 4, 2014, entitled &ldquo;Cellectar Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed or Refractory Multiple Myeloma&rdquo;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="font-size: 10pt; text-align: center">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Press release dated September 5, 2014, entitled &ldquo;Cellectar Biosciences Announces Participation in Two Upcoming Investor Conferences in September&rdquo;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v388646_ex99-1.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>Cellectar
Biosciences Announces Acceptance of Investigational New Drug Application to Evaluate I-131-CLR1404 in Clinical Trials in Relapsed
or Refractory Multiple Myeloma </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wis., September 4, 2014,</B>
&ndash; Cellectar Biosciences, Inc. (NASDAQ: CLRB), announced today that the U.S. Food &amp; Drug Administration (FDA) has accepted
the Company&rsquo;s investigational new drug (IND) application to begin clinical study of I-131-CLR1404, a highly-selective, cancer-targeting
radiopharmaceutical, in patients with relapsed or refractory multiple myeloma, an incurable cancer of plasma cells.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I-131-CLR1404 is radiotherapeutic comprised
of a proprietary phospholipid ether (PLE) analog, acting as a cancer-targeted delivery and retention vehicle, covalently labeled
with Iodine-131, a cytotoxic radioisotope that is already commonly used to treat thyroid and other cancer types. Because Cellectar&rsquo;s
PLE platform has been shown to reliably and universally accumulate in malignant cancer cells, and the therapeutic properties of
the Iodine-131 isotope are well known, I-131-CLR1404 is engineered to combine an intracellular radiation mechanism of destroying
cancer cells, including cancer stem cells, through targeted delivery specific to malignant tissue that spares critical normal tissues
from consequential radiation dose.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar plans to initiate a Phase I/II,
proof-of-concept trial during the fourth quarter 2014 in approximately 20 patients with relapsed or refractory multiple myeloma
that have previously been treated with, or are intolerant of, an immunomodulator and a proteasome inhibitor. The primary objective
of the study will be to determine the safety and tolerability of I-131-CLR1404, with and without concurrent weekly dexamethasone.
In addition, the trial will seek to identify the recommended dose for future pivotal trials and determine therapeutic activity
of I-131-CLR1404 in this patient population as measured by overall response rate, time to progression and duration of response.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&ldquo;This trial affords us an opportunity
to both assess the safety of I-131-CLR1404 in patients with multiple myeloma, but also to obtain near-term proof-of-concept data
characterizing the activity of I-131-CLR1404 in this difficult-to-treat patient population,&rdquo; commented Dr. Simon Pedder,
president and chief executive officer. &ldquo;Having initiated a Phase II diagnostic imaging trial of our lead compound, I-124-CLR1404,
in glioblastoma earlier in the year, we are pleased to now have this opportunity to initiate a second, company-sponsored clinical
trial with the potential to showcase the therapeutic applications of our targeted delivery platform.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Multiple Myeloma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">According to the National Cancer Institute,
multiple myeloma is the second most common hematologic cancer and results from an abnormality of plasma cells, usually in the bone
marrow. It is estimated that 70,000 people are living with multiple myeloma and 24,000 new cases are diagnosed annually in the
U.S., and that nearly 230,000 people are living with multiple myeloma and approximately 114,000 new cases are diagnosed annually,
worldwide.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar Biosciences is developing agents
to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as
a targeted delivery and retention vehicle, Cellectar&rsquo;s compounds are designed to be selectively taken up and retained in
cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery
platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer
cells to &ldquo;find, treat and follow&rdquo; malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum,
cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored
Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted
molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells.
A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of
2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted,
non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional
information please visit www.cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kate McNeil, Vice President of IR, PR &amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (347) 204-4226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: kmcneil@cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements.&nbsp; You can identify these statements by our use of words such as &ldquo;may,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plans,&rdquo; or
their negatives or cognates.&nbsp;&nbsp; These statements are only estimates and predictions and are subject to known and unknown
risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.&nbsp;
These statements are based on our current beliefs and expectations as to such future outcomes.&nbsp; Drug discovery and development
involve a high degree of risk.&nbsp; Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our&nbsp;pharmaceutical collaborators&rsquo; ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>v388646_ex99-2.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><img src="logo.jpg"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>Cellectar
Biosciences Announces Participation in Two Upcoming Investor Conferences in September</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 13.5pt; text-align: center; text-indent: 0in"><I>Rodman &amp;
Renshaw 16<SUP>th</SUP> Annual Global Investment Conference on September 9, 2014</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><I>Aegis Capital
2014 Healthcare and Technology Conference on September 11, 2014</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><I>Webcasts
Available Through Cellectar Corporate Website</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>MADISON, Wis., September 5, 2014,</B>
&ndash; Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical stage biopharmaceutical company developing innovative agents for
the detection and treatment of cancer, announced that Dr. Simon Pedder, chief executive officer, will be presenting a company overview
at the Rodman &amp; Renshaw 16<SUP>th</SUP> Annual Global Investment Conference being held September 8 - 10, 2014 at the New York
Palace Hotel in New York and the Aegis Capital Healthcare and Technology Conference being held September 10 - 13, 2014 at the Encore
at Wynn in Las Vegas.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<tr>
    <TD STYLE="text-align: justify; width: 20%"><font style="font: 10pt Times New Roman, Times, Serif">Event:</font></td>
    <TD STYLE="text-align: justify; width: 80%"><font style="font: 10pt Times New Roman, Times, Serif">Rodman &amp; Renshaw 16th Annual Global Investment Conference</font></td></tr>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Date: </font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Tuesday, September 9, 2014</font></td></tr>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Time:</font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">1:40 p.m. Eastern Time</font></td></tr>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Location:</font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">New York Palace Hotel, New York, NY</font></td></tr>
<tr>
    <TD>&nbsp;</td>
    <TD>&nbsp;</td></tr>
<TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Event:</font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Aegis Capital Healthcare and Technology Conference</font></td></tr>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Date:</font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Thursday, September 11, 2014</font></td></tr>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Time:</font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">2:30 p.m. Pacific Time (5:30 p.m. Eastern Time)</font></td></tr>
<TR>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<tr>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Location:</font></td>
    <TD STYLE="text-align: justify"><font style="font: 10pt Times New Roman, Times, Serif">Encore at Wynn, Las Vegas, NV</font></td></tr>
</table>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Live audio webcasts of both the Rodman
&amp; Renshaw presentation and the Aegis Capital presentation will be available on the Company&rsquo;s website on the Investor Relations
Events page at http://investor.cellectar.com/events.cfm. The webcast replays will be available approximately two hours after each
presentation ends and will be accessible for 90 days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cellectar Biosciences, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cellectar Biosciences is developing agents
to detect, treat and monitor a broad spectrum of cancers. Using a novel phospholipid ether analog (PLE) platform technology as
a targeted delivery and retention vehicle, Cellectar&rsquo;s compounds are designed to be selectively taken up and retained in
cancer cells including cancer stem cells. With the ability to attach both imaging and therapeutic agents to its proprietary delivery
platform, Cellectar has developed a portfolio of product candidates engineered to leverage the unique characteristics of cancer
cells to &ldquo;find, treat and follow&rdquo; malignancies in a highly selective way. I-124-CLR1404 is a small-molecule, broad-spectrum,
cancer-targeted PET imaging agent currently being evaluated in a Phase II glioblastoma imaging trial. Additionally, multiple investigator-sponsored
Phase I/II clinical trials are ongoing across 11 solid tumor indications. I-131-CLR1404 is a small-molecule, broad-spectrum, cancer-targeted
molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells including cancer stem cells.
A Phase Ib dose-escalation trial of I-131-CLR1404 in patients with advanced solid tumors was completed in the first quarter of
2014 and results presented at the American Society of Clinical Oncology (ASCO) 2014 Annual Meeting. CLR1502 is a preclinical, cancer-targeted,
non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. For additional
information please visit www.cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>INVESTOR CONTACT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Kate McNeil, Vice President of IR, PR &amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Cellectar Biosciences, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Phone: (347) 204-4226</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Email: kmcneil@cellectar.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This news release contains forward-looking
statements.&nbsp; You can identify these statements by our use of words such as &ldquo;may,&rdquo; &ldquo;expect,&rdquo; &ldquo;believe,&rdquo;
&ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;could,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plans,&rdquo; or
their negatives or cognates.&nbsp;&nbsp; These statements are only estimates and predictions and are subject to known and unknown
risks and uncertainties that may cause actual future experience and results to differ materially from the statements made.&nbsp;
These statements are based on our current beliefs and expectations as to such future outcomes.&nbsp; Drug discovery and development
involve a high degree of risk.&nbsp; Factors that might cause such a material difference include, among others, uncertainties related
to the ability to raise additional capital, uncertainties related to the ability to attract and retain partners for our technologies,
the identification of lead compounds, the successful preclinical development thereof, the completion of clinical trials, the FDA
review process and other government regulation, our&nbsp;pharmaceutical collaborators&rsquo; ability to successfully develop and commercialize
drug candidates, competition from other pharmaceutical companies, product pricing and third-party reimbursement. A complete description
of risks and uncertainties related to our business is contained in our periodic reports filed with the Securities and Exchange
Commission including our Form 10-K for the year ended December 31, 2013. These forward-looking statements are made only as of the
date hereof, and we disclaim any obligation to update any such forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X``02D9)1@`!`0$`8`!@``#_VP!#``(!`0(!`0("`@("`@("`P4#`P,#
M`P8$!`,%!P8'!P<&!P<("0L)"`@*"`<'"@T*"@L,#`P,!PD.#PT,#@L,#`S_
MVP!#`0("`@,#`P8#`P8,"`<(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,
M#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`S_P``1"`!+`1<#`2(``A$!`Q$!_\0`
M'P```04!`0$!`0$```````````$"`P0%!@<("0H+_\0`M1```@$#`P($`P4%
M!`0```%]`0(#``01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T?`D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0`'P$``P$!`0$!
M`0$!`0````````$"`P0%!@<("0H+_\0`M1$``@$"!`0#!`<%!`0``0)W``$"
M`Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O`58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H`#`,!``(1`Q$`/P#]_***X#]I
MG]I[P7^R'\)-0\:^.]7CTG1;#"*`-]Q>S$'9!!&.9)6(X4>A)(4$C2E2G5FJ
M=--R>B2W;!NVK._KSSXE_M;?##X.:]:Z3XH\?^$M$U>^N([2"PNM4A6[EED8
M(B"'=O)+$`<=Z_$#]NG_`(+E?%G]K'4KW2O"U]>?#3P*Y,<=CIEP4U*]CY&;
MFZ7Y@2#S'$54="7ZU\K?`(A_VB?`D\K%YI?%&F-)*YW.Y-Y%R6/)/N:_2LO\
M-ZTJ+K8ZIR.U^5:OYO;[K^IRSQ2O:*/ZJZ_/7_@XD_:R\9_LS_LZ>";+P)XG
MUCPIK?B?79#)>Z9/Y%RUO;V[.T8<<@&1X<XZXP>"0?T*K\__`/@L3^Q=>?MJ
M?&WX2Z;%KT6G6V@.S26KQ%Q/]HN8%<Y'0[(2/QKX/)\SR[+\=2Q6:24:2>MT
MVKM-15DGN[=#3$2Y8,^V/@A-J\_P7\(2>(+EKS7I-%LVU*=D"&:Y,">:Y`P`
M2^XX`P,UL>+/%NF>`_#&H:UK6H6FE:1I4#W5Y>74HBAMHD&YG=CP%`&<FF^*
MO%6E?#SPG?ZSK%]::3HVCVSW-W=7#B.&UA1<LS$\``"OQL_:=_:D^)G_``78
M_:)3X/\`P>ANM'^$VDSK<7]_<(\<5U$KX%]>XY$>03#;?>=@&;D?N^S*,GGF
M-6=234*4=9R>T5V7GV14ZG*K;L^\OV$_^"N'A']OS]H'QOX*\)^&O$%MIWA6
MU%]::[<;3;:I#YHBW%``T!9CN17R70,?E*E:^LZ\C_8K_8K\%_L*_!>T\'>#
MK0\D3ZGJ<Z@WFL7.,-/,P[]E4?*BX`&.OKE<6:SP<L3+ZC%QIJR5W=NW5]K[
MVZ%0YK>]N%%%%><4%%%%`!1110`4444`%%%%`!1110`4444`%%%%`!1110`4
M444`%%%%`!1110`4444`4O$OB2P\&^'-0UC5;N&PTS2K:2[N[F9ML=O#&I=W
M8]@J@DGT%?S>?\%+O^"@.M_\%!?VA+O7I9KJV\%Z*\EKX7TIB52UMLX-PZ]/
M/FP&8GE1M0<+S^J?_!Q5^T?<?!_]B.V\(:?.T&H?$[4UTN4J<-]AA7SKD9]&
MQ%&?592*_#[X;?#S5OB[\1=`\)Z%#]IUOQ-J,&EV,9Z---($4G_9!.2>P!K]
M@\.\GITZ$LTK+5W46^B6[^>WHGW.+$S;?(CV/]@'_@G3X[_X*%?$>;2O#2QZ
M5X>TEE_MKQ#=QEK73@1D1JHP99V'*Q@CCEBJ\G]KOV4/^",7P(_94MM/NX?"
ML'C'Q19,DO\`;GB)5O9Q*N"'BB(\J'##*[$!''S$C->Q_LB?LN>'?V-_V?O#
MWP_\,PJMGHT`^T7)0++J-TPS-<R>KR/D^PPHX4"NV\7^,],\!Z))J&K7<=I:
MQG&YN6=NRJ!RQ/H*^0XIXWQ&+G/V=3V="-^MKKO)^?;9>NIK3I1@KR-2O*?B
M!\);J\^-^G^,KS4+"WT+2(DEF\UBKQ>6&/IC!8@YR._%55_;2\,&_P#+-EK0
M@SCSO)0CZ[=V<?K1\7O#6J?M%:5HC^&-8LI/#DSG[9EBI5P1AF7&6*C/R'&#
M@^X_'<TS3`9CAFL(_;SIN,E"+LVT]&^\4WKTL34J0G'W=6NAY=^T#:ZC^WM:
MZCX#TP/:>&9U_>S2*=O!XFE'<9&5C[GD\_=]<_8\_8W\$_L0_"&W\(>"K#R(
M2_VB_OI0&N]5N"/FFF?N>P7[JJ`H``IWBKP/K_PE^'VGZ;\/+.*6X>?_`$V:
M0(T\F5_UAWD*23^0Q@8KP;]K#]D/X\_M2?!^[\/Z=\0'\&W]W,CFY&IS0`(#
M\RD6H!(([9Q77P_CL=AZZRS'2J2=:<93DE^ZA=65M=5%;^9$.:$KR3<G]Q]9
M>*?B1X=\#20IK>OZ+H[W+K'$+Z^BMS*S'"JN]ADD\`#K6U7Y3^!O^#8/2M8O
M(KWXC_&#7]?N'8-<1Z;IRPO(,\CSYWE?GUV@U^J&D:7%H>DVME!O\FSA2"/>
MQ=MJJ%&2>2<#J>M?>YKA<!0Y5@Z[JO6_NN*6UK7=WU.J$I/XE8L45XW\=OV[
M?`'P%\;0^$KF?6_%'CBYC6>/PQX8TR75]6$9Z2/%$"(4/9I60'MFN3N?^"D5
MGX9A-YXJ^#WQW\):.GS2:I>^%/M5M;)_?E%I+-(BCOE..]<]/+,5.*G&#L]N
ME_1/5_*Y3DCZ0HKGOA9\6/#7QN\"V'B;PCKFF^(M`U--]M?6,PEAD&<$9'1@
M>"IP0000#70UQ3C*$G&2LUT'<****D`HHHH`****`"BBB@`HHHH`**BO;^#3
M8#+<S101+U>1PBC\33K>YCNX5EBD26-QE71@RM]"*?F`^BBBD`4444`%%%%`
M!1110`4444`?C5_P=!>(KB?XU_"322[?9;71-0O%7/&^2>%"?KB,5\[_`/!"
M?P?:^,/^"GW@`7B+*FD6VHZG&K=/-CM)%0_4&3/X5]5?\'0_PWF6_P#A!XR1
M&:`C4-#G8#A'/E3Q`GW"S?\`?)KXB_X).?&ZU_9]_P""A_PP\0:A-';Z;<ZD
MVC7DLAVI%'>1/;!V/8+))&2>P%?NV2IU>%'"COR5%\[R."H[5M>Z/Z4*^5_V
MO?$]SJ_Q6;3G=OLNDP1K%'_#N=0[/]2"!]!7U17A'[5_P2O]?U%/$ND6\EY(
ML0BO;>,;I"%^[(H_BP."!S@`^M?RMQ[A<3B,JE'#)NTDY);N*O\`?9V?R-<9
M&3I^Z?/5>N?L;^*+C3/B5/I0=C::I;.[IGY1)'@A_K@D?EZ5Y*()&N!"(Y3,
M3CRPAWY],=<U]&?LH?!.^\*33^(M8@>UN;B+R+2WD&)(T)!9V'\).``#SC.>
MM?E'!N$Q-7-J4\.G:+O)]$NM_5:?,\W"QDZB<>A[=7S+^T-_P5\^!/[+7Q>U
M7P+XT\3ZEIWB31EA:ZMXM%N[A$$L2RIAXXRIRCJ>#QG%?35?S*_\%)?C9;?M
M$?MX?%+Q98SK<Z;>:V]I8S+RLMO;(MM&X]F$.X>S5_77!W#]+-<3.&(;4(QO
M=66K:MNGTN>M7JN"5C]^OV1O^"BGPI_;CU;7+'X<ZY>ZO<^'(89[Y9],N+,1
M)*SJA!E10V2C=,XQ7;?M/_%F3X#_`+-_CWQK#$)[CPIH%[JL,;#*R20P/(BD
M>A91GVK\X?\`@UZ^',UKX&^+GB^6)Q!J.HV&CV\A'#F"*260#Z?:(Z_3[XD^
M`=/^*OP[U[POJR-+I?B/3Y],NT'!:*:-HW`]]K&N#/<#A<!FLL-3O*G!QO?5
M[)M:)>:*IR<H79Y!_P`$Z/V?-/\`@E^S5H.IRL-4\:>.[2'Q'XKUZ<;[S6M0
MN8Q-(\DAY*(7V(N=JHH``YS[S7QQ^SI^UPO[$?A'2OA%^T%/-X5O?"<2Z5H/
MC2ZA<:!XKL(@$MY/M0!2"Y$059(I2IW*2"P:O6?%_P#P4F^`7@C1S>WOQ?\`
M`,T9&4BL=8AOKB8]@D,!>1R>P5236&88'&5<3*HHN?,VTTFTUTM;I;ITVLK6
M*4DD>D?#SX,>%?A+J&O77AG0=-T.;Q1?'4]5^Q1");VY*!#,RCY=Y"C)`&3R
M<G)KXP_;.TSX3^)?^"F]EI_QI\1VFA^%(OAC%<6`OO$T^B6SWO\`:LRY#1S1
M;W\K=P2>!TXKZJ_9A^/^I?M'^$=0\0S^!_$?@O1FO3%HAUQ5@O-8M`JD79MO
MOVZLQ8*DGS%0&P,XKYK_`&E/BY\+O@Y_P57AU#XL:CX:TW0[OX4Q6]G)K<"R
MP/<?VO*VU0RL`^P,?IFNG*8UXXNI&?,YJ+^%WETV:OJMO+8F5K(9X!_9H_8I
M^*OBZS\/^&?%.A>(-<U`L+6PT_XE7]Q<W!5"[;$2\+-A59C@<`$U]=?!OX->
M'_@%\/K/POX7M;FRT6P:1X89[V>\D4R.7;,DSO(<LQ/+''08%?/>A_\`!07]
MD#PQJL5_IOC?X5Z??09\JXMK2.&6/((.&6,$9!(X/0U[[\$OC[X-_:/\&-XB
M\#>(M/\`$^B+<O9F\LG+1"9`-Z9('(W#\ZRS5XUQ3JJKR?W[M7U[I+;Y[CC;
MI8\9_P"">6H7-]XW_:-6XN;FX%O\6-1BB$LK.(D%G9$(N3\J@D\#`Y-?2M?"
M/[+?[;GPF_9H^,'[1.B>/?'N@^%]7O/BEJ%[#:7TC)))";6S02#"D;2R./JI
MKW'0/^"I?[/7BC7K'2]/^+/A.[U#4[B.TM8(YV+SRR,$1!\O4L0!]:K-,MQ<
MZ[J0I2<;1U47;X5UL$9*VYB_M^:A<V7QF_9E2"YN8$N/B;'',L4K(LR?V9?G
M:P!^9<@'!R,@5]+U\E?\%1OB!HOPI\:?LY^)/$>I6^D:%HOQ)CN;Z]N"1%;1
M_P!F7PW,0#@9('XUUO\`P]H_9O\`^BP^#_\`P(?_`.)J*N!Q%?"4)4*<I*TM
MDW]I]D',DW<^B*_+7]DCPC^RQXP^&FKWWQ?\<:+9^.W\5:\EY#J7Q!N].N(X
MEU2Y6`&%;I`H\H)C"C(P:_1OX)?'WP;^TAX,;Q%X%\1:?XGT1+E[,WEDY:(3
M(`73)`Y`9?SKX/\`V#?VIOV;/A?\#]1T;XD:_P##JQ\6VWBWQ"UU#JUE')=H
MC:O=M'N9HR2"A4CD\$?2NO*(5Z="O&,:BDI034+J2TGOHW;OYV%-JZ/9/@E^
MP]^RK\9WDU;P!=P^+%T*[B,T^D^/=2OH[688D17V7;*#P#M;J.Q%>T_MJ_M%
M/^RE^S#XL\=06"ZKJ.D6R1Z;8LVU;R]GE2"WC8CD*9I$SCG&:\T\+?\`!2_]
ME/P+!-%HOQ(^'6CQW#!Y4L4%NLK`8!8(@R<<9->B?MJ?`&7]K3]E3Q1X.TR_
MAL-3U>VBN](O9%+107D$J7-M(V.=GFQIG'.TFN:O[9XND\P4_9\R_B7O:ZYN
MWSL-6L^4\U^''_!,;POXQT>VU[XZ27'QA^(>H1B?4KK6KB232["5N6M[*R#"
M"&!"=J_(68#).3@:\7_!-WPO\,/%.G:_\'M7U?X0ZK:74<EW;:5+)<Z-K$`8
M>9!<:?*_DG<N0LD>QT)!!.,'.^%W_!4#P18Z=;Z%\8[A?@U\1K!!#JND>)`;
M.UDF48:6TNF'D7%NYRR,CDX(R`:T;S_@IO\`#[Q=XRTKPS\+QJ/QB\1:E=Q0
MS0>%H_/L]+@+@27-S>-BWB1%);!<LQ`4#)S6M3^V>=IJ7+_Y3M_Z1R]N@O</
M1OVA?V4/`_[4MKI,/C;3;_48]$>22S%MJUYIYC:0*')-O+&7R%'#9QVQDU\>
M?%7_`()Z_"SPW_P4"^$7@BRTKQ##X9\4>'=?OM3LO^$IU1A<S6QL_(?<;C>N
MWS9.%(!W<YP*_0FOF'XY?\I6/@'U_P"12\5?ST^L<GQ^)A*5*%22BH5&DF[)
M\DG>WKKZZCFEO8[_`.!'["7PS_9K\:2^(/!^CZI8:K/:O9/)<:]J%\AB9E8C
MRYYG0'*+\P&1CKR:R?\`@H'^T)J_P0^"L&E>#PEQ\2_B)?1^%_!]L3DB^N`0
M;EAVCMX@\S'H!&`>M>ZLVT$DX`Y)/:O@SP]X/^)?[??[4FJ_&SP%XTT+P?X4
M\!RW?@_P1-JGA\ZQ'J2!@NH:E"AFB">9,AA209+1Q$<`G,Y??$UWBL9.\8*[
M<FVF_LQ>[U>Z7V4V$M%9'0_LN>#K[_@F]^TYI/PDU37]9\0>`_BOIRWGA[5=
M6NGN);?Q#:PJ+^U9W8D"ZC47"+G`9)%45]I5\5_M)?L+?M$_'[X=+I^J?&[P
M7?7NB7D.N:*UOX&^PW%MJ-LWF6\D<XNF,1WC:6VGY'8$$$BO?_V+OVDX_P!J
MK]GS1O%$UHVEZ]$9-,\0Z6XQ)I&J6[&*ZMF!Y&V125SU1E/>KS:"K4XXR,U.
M6TW&^_V7JH_$E9Z;IMO4(NVA\J?L._L._#+]I7P'XV\4>.++6]6UZ3X@^);0
MS_\`"3ZE;`11:G.D:!(KA4`50`,#M7I'Q7_X)E?`;P'\.-:UN'4/$W@&;2;2
M2[C\0VOC?4XI=)9%+"8&2Y9#M(SA@0>F.:\X_8)_8"^#W[1?PZ\;^)_&O@;3
M=?UZ;XB>)[>2\GFG1W2/59U1<(ZCA>.E,_;$_P""8GP^_9YU'PY\7?`/PQTS
MQ)I'@:4R^*O!,T<E]!K6FDYDNK>*5F!O+;'F(IR)%5E(SC/MUL5S8^5!8JI%
MW:2M[M^D4^>UGLFXV[JQ"7NWL?3/_!.GXH^)_C5^P]\,_%/C(R2>)-:T6*>\
MFDB\I[OEE2<KV,L823T^>BO2_A=X^T'XI_#G0_$?A:]M-1\.:U917>G7%MCR
MI(&4%-H'3`XV\$$$$`C%%?&XR?-7G)1Y;M^[VUV^6QJMCPW_`(*P?LAS?MI?
ML2^*?"VFPB?Q-IH36]!7H7O;?++$/^NJ&2+_`+:Y[5_-O+$Z,\<B2PRQL4=&
M!22)@<$$=58$8]017];%?CW_`,%QO^"0^HZ7XGUCXW?"W29K_3M1+7GBW0[.
M,O+:2]7U"!!RR-UE0#*MF09!?;^C>'W$=/#R>78F5HR=XM[*75?/2WGZG-B:
M=_>1]._\$8_^"I>F?MC?"FP\#>+=2BM_BOX7M!#.D[A6\16T:X6\BS]Z3:!Y
MJ#D-EONL,?<]?R8>'?$5]X9UJQU?2+^[T[4M/E6YL[VSG:&>VD4Y5XY%(*L/
M4&OT-_9>_P"#C_XH_"C2;72OB+X>TSXDV=LH0:@DW]FZH5`P-[*K12GWV(3W
M)/-=/$GA]6E6EB,LLT]7!NUGY-Z6\G:W2XJ>)5K2/V^%I$)S+Y4?FG^/:-WY
MU)7YAO\`\'0'P]&E[U^%OCPWN/\`4F[LQ'G_`']^<?\``:^;_P!JC_@XR^*_
MQDTFZTCX?Z+IOPQTZY!1KY)O[0U;:1@[)&58XC[JC,.S`\U\OA.!,XJSY'2Y
M%U;:M^#;?R1K+$074^S/^"V__!4O3?V7_A7J7PR\&:I%<_$[Q5:M;7+6[ACX
M:LY%P\\A'W9W4D1)]X9\PX"KN_"K3]/GOKFWL[.WFNKJYD2WM[>%2\D\C$*D
M:CJ69B`!W)%/UC6+G6=2N]1U&\N;V^O96GN;JYE:6:XD8Y9W=B69B>I))-?K
M3_P0U_X)#ZCH6O:5\</BGI4MA/:@7/A'0;N/;-&Q'&H7"'E&`/[I&&X9WD`[
M,?J-&E@N%\L<I/FD_DYRZ)=DOP5WN<C<JLS[O_X)G_LFG]BW]C+P?X(NEC&N
MI`VHZXZ<A[^X/F3#/<(2(P>ZQK7O5%<G\>I6@^!GC1T=HW30KYE=20RD6[\C
M'<5^%5J]3%XF56J_>F[M^;9Z'PJR.EU32K76["6TO;:"\MIAMDAGC$D;CT*G
M@CZUSOAOX&^"?!NJB^T?P?X6TJ^!W?:+/2;>"7/KN1`<_C7QK\&_V=)]>^#'
MA2_/[.]KK4M[HMI.=1D^(<EN]^6@1O.*]4+D[L=LX[5TVH>*+K6/^"6NEFXU
M>_U#5-+UBPTR]FFE9IH)X=<BB>W,FXF01;?*$FX^8J!OXL5ZDLL<&J=.KHY*
M+VZWU]V<NW6WYVCVG='V;5:?3;/4W$DL%M<,ORAF17(]LFO!/VG]OQ`_:5^'
M?P^\1ZG>Z5X$U^PO[V>&WNGM%\0WT+0B*QDE0JVP1O)+Y88>9LP<A2*YK]H7
MX.^%OV3&\(^)/AI"?"OBR]\1:?I<&D6%S(+?Q-#-<(D]O+;EBK[8B\GF!=R&
M/.[&:XZ.!C+DBYM2FKK33=K5WTVULG;KULW/?R/IQ]`TV-2S65DH'4F%`/Y5
M9M+2&RBV011Q(3G;&H49]>*^9OVC_@!KWQ+_`&A+O6(--\$_$S2K?2K>W3PO
MKNM3V3:')ND+3I'&DD;><"N6D0,/+`4XS5K]E;5[7X8?$;Q;X#3P!=>"?$ZZ
M/'X@CTRW\1OK&DW$.]X5,.XC[.QDX*>6FX8/(%.6!3H>TC.[LFUII]\N;2^_
M+;Y:AS:VL?0]QHUA),7EM+-I)3RSQ*68_B.32IX?L(W5A96@93D$0J"#Z]*^
M7OV3_P!GSP-^U%\%--\<^/(/^$Z\9ZZ9)-8GU&ZE=M(N@[![**$,%MEA(V!5
M"M\N223FNT^(_AS1/`G[$'Q1TSPQXCO]>T_3=$UB*.2?5O[1ETUUMY,VHFR7
M`B/`5V++T)Z45<'&-7V"FW)247IIO;1W^ZZ5P4KJY[G=V,-^@6>&*=5.0)$#
M`'UYJ#_A'-/_`.?"S_[\+_A7RK^U=I%SXJ_9_P#@%ID.G1Z]+JFM:9"VG7&H
MR6,.H@Z9<,8Y)T!95XSG!Y4<5V/[.'[)^E^'/%1US6_AAH7@[5='D272Y]/\
M4WFK>8Q5U<LLBQJN`0!D-G<>F*<L%"%#VLZCOKHDNCMUDG]R=@YVW:Q]`VMG
M%8Q%(8HX4)SM10HSZX%5V\/6#L6:QLRS'))A4D_I7RSXK\$^+=<_;:^)OB/P
M1JLT/BGPCI&AR6FF75RRZ9K<$J71GLYEZ(7\M"DH&8W4$Y4L*V?A9\<+#XY_
MMJ^&]2TXWUD\'@;4[74])NR8[G2;V/4+19()XL_+(IR`>C*05)4@TY9;)1YX
MRNN7F?DW'F2?JMGZASGT8^@:;&I9K*R`'<PH!_*KH&`!Z5\N_"GX6^&_VK/B
MO\3;OXE*WB36?#'B6XTBR\/7MRXM-%L$5#;RI;!@K-.K>89F!+9P"`N*];^#
M/PL\(_![5O$>C^$]8NO+412W&@-JQO(=%)5MK1Q.6>`2#)VYVG;E0.:QQ&&A
M3O%R;DDGMIK;K?SWM9_<-2N=YK7A^P\1VOD:C8VE_#G/EW,*RI^3`BG:5HUI
MH5H+>RM;:S@7D1P1+&@_``"O@S]D3]FF?XE?";PAJFI?";P[KNGZH=UUKUSX
MVO8;R>(SL&F-LL94.%!P@?!P.1GCZ!_:>_9\FU3X3>#O"'@Z\T33M.TG4T8>
M'-5U.XM;7Q%;I%)_H;3(3,<$B3'S`^7\P(KIQ&7TJ598?VO5IZ*RMZ2>OD[>
M;1*FVKV/>DD$@RK!AZ@YIK6Z/,DK(AD0$*Q4%E!Z@'MFOD'PIX?M/V9_B[X.
MU/Q!\'M.\#KKFK1Z%:ZEX5\62W%L]Q<*R1I<696+S4)R=Q5]A`;'&:^P:XL9
MA51:Y7=-;Z?I*2_'Y%1E<",@@\YIEO;QVD*Q1(D<:#"JBA57Z`4^BN.Y04R&
MVCMRYCC1#(V]]J@;F]3ZGWI]%%P&06\=LI6-$C#$L0J@`D]3QW-/HHHN`RVM
MH[.%8H8TBC7HB*%4<^@HI]%#8!1110!\%?MV_P#!`SX:_M1:K?>)O!-S_P`*
MS\97C-+.;2V$NDZC(<DM+;`KL<GJ\17/4JQK\V_C3_P0I_:2^#U[.+;P=:>-
MK"-B$O/#NH13^8/7R93'*/IM/UK^AFBOL,KXXS3!05/F4XK92UMZ--/[VS&=
M"$M=C^9$?\$V_P!H0W7D_P#"E/B9YG_8#F"_]]8V_K7KGP3_`."#W[2'QAO8
M?MWA2P\#:?(1ON_$.H1QM&/40PF24GV(7ZBOZ$J*]>OXF9A*-J=.$7WU?Z_Y
MD+"QZL^&?V#?^"$7PQ_9(U:Q\3>*)F^)/C>S(E@NK^W6/3M-D'.Z"VRP+@])
M)"[#@KL-?<U%%?#9AF>*QU7VV*FY2\^GHMDO0WC%15D%5M9TBV\0Z1=Z?>PI
M<V=]"]O/$_W98W4JRGV()%6:*XDVM44>,Q_\$]/@Q#$L:^`=)5$`55$DP4`=
M`!OZ5WDGP.\(2?#:V\'#P]I<?A>T:)H=,BA$5O&8I5E0A5QR)%5L]R,G-=51
M714QN(G;GJ2=M5=MV?<7*ELC!^)'PM\._&#PQ)HOBC1K#7-,D<2&WNXA(JNO
MW74]5<=F4@CL:YCX:?LF?#OX0^)1K6@^&+6WUA(S%'?7$TUY<P(>JQR3.[(#
MT(4C(KT6BHCB:L8.G&347TN[?<#2W.`^)W[+7@#XQ>((]8\0^&;*[UF*,1+J
M,+R6EYL'1#-"R2%1V!;`J_\`"CX!>#_@?'>CPMH-II4NI,K7=P"\US=%?N^9
M-(6D<#)P&8@9.*["BF\56</9.;Y>UW;[@LKWL>7^.?V,/AC\1O%-WK>J^$[1
MM4U`[KRXM+B>R:]/K,(702G'=P2:ZK2_@SX5T/X:3^#;+0-+LO"]S:R6<NF6
M\`BMY(I%*R*57&=P)R>IR23FNFHIRQ5:45&4VTMM7IZ!9=CCOB#^S_X-^*O@
MW3?#WB'0++5-&T=XY+*UEW!+9HT,:%<$$$(2!ST-<WX6_8B^%7@GQ+8:SI?@
MW3K/4]+G6YM9TEF+0R+T89<C(]Q7JM%..,KQCR1FTNUW;4&EV,G3/`FD:-XO
MU77[6P@AUG6XH(+Z[4'S+E(0XB5O9=[X_P!XU0L_@[X7T_XHW7C:#0]/A\67
MUF-/N-4CCVW$\`*D(Y'W@"J\GG"@9P!72T5E[6>NKU5M^G;T\AG`?%/]EOP#
M\:=<AU3Q'X;M+W5H(_)2_AEEM+OR_P"X9H61RO\`LEB/:M;X6?!+PG\$]%GT
M_P`*Z#I^BVUT_FW'D)F2Y?\`OR2-EY&QW8DUU-%7+$UG#V3F^7M=V^X5E>YX
MVO\`P3X^#*9"^`=)0$DX6291DG)X#XZUT^J?LO?#[7/AG8>#KWPGI%YX;TIB
M]E93QF06;%BQ>-R=Z-EF^96!Y/-=[15SQV)E9RJ2=M5J]&'*NQYIX$_8^^''
MPW\56NN:7X9A_M>P!%I=7EU<7TEID8)B,[OY9QQE,''%>ET45E5KU*KYJDG)
8^;N-)+8****R`****`"BBB@`HHHH`__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
